Abstract:Cystic fibrosis (CF) is the most common monogenic autosomal recessive disease in Caucasians caused by pathogenic mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene (CFTR). Significant small molecule therapeutic advances over the past two decades have been made to target the defective CFTR protein and enhance its function. To address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in CF, two biomolecular activities are required, namely, correctors to increase the amount of properly folded F508delCFTR levels at the cell surface and potentiators to allow the effective opening, i.e., function of the F508delCFTR channel. Combined, these activities enhance chloride ion transport yielding improved hydration of the lung surface and subsequent restoration of mucociliary clearance. To enhance clinical benefits to CF patients, a complementary triple combination therapy consisting of two corrector molecules, type 1 (C1) and type 2, with additive mechanisms along with a potentiator are being investigated in the clinic for maximum restoration of mutated CFTR function. We report the identification and in vitro biologic characterization of ABBV-2222/GLPG2222 (4-[(2R,4R)-4-({[1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl}amino)-7-(difluoromethoxy)-3,4-dihydro-2H-chromen-2-yl]benzoic acid),—a novel, potent, and orally bioavailable C1 corrector developed by AbbVie-Galapagos and currently in clinical trials—which exhibits substantial improvements over the existing C1 correctors. This includes improvements in potency and drug-drug interaction (DDI) compared with 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid (VX-809, Lumacaftor) and improvements in potency and efficacy compared with 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)indol-5-yl]cyclopropane-1-carboxamide (VX-661, Tezacaftor). ABBV-2222/GLPG2222 exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR with an EC50 value <10 nM.SIGNIFICANCE STATEMENTTo address the most prevalent defect of the defective CFTR protein (i.e., F508del mutation) in cystic fibrosis, AbbVie-Galapagos has developed ABBV-2222/GLPG2222, a novel, potent, and orally bioavailable C1 corrector of this protein. ABBV-2222/GLPG2222, which is currently in clinical trials, exhibits potent in vitro functional activity in primary patient cells harboring F508del/F508del CFTR and substantial improvements over the existing C1 correctors.

Localization and function of humanized F508del-CFTR in mouse intestine following activation of Serum Glucocorticoid kinase 1 and Trikafta.

CFTR modulator therapy for cystic fibrosis caused by the rare c.3700A>G mutation

A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants

KDM2A and KDM3B as Potential Targets for the Rescue of F508del-CFTR

Elexacaftor Mediates the Rescue of F508del CFTR Functional Expression Interacting with MSD2

F508del-CFTR rescue: a matter of cell stress response

Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation

Src kinase inhibition reduces inflammatory and cytoskeletal changes in ΔF508 human cholangiocytes and improves cystic fibrosis transmembrane conductance regulator correctors efficacy

Trikafta rescues F508del-CFTR by tightening specific phosphorylation-dependent interdomain interactions

Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment

Stabilizing Rescued Delf508 CFTR at the Plasma Membrane by Potentiation of Its Interaction with Na+/H+ Exchanger Regulatory Factor 1

Correction of CFTR function in intestinal organoids to guide treatment of cystic fibrosis

Searching for Combinations of Small-Molecule Correctors to Restore F508del–Cystic Fibrosis Transmembrane Conductance Regulator Function and Processing

A Lesson from a Study with the F508del-CFTR Mutant

Effects of ivacaftor on systemic inflammation and the plasma proteome in people with CF and G551D

CFTR modulators response of S737F and T465N CFTR variants on patient-derived rectal organoids

Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators

Biological Characterization of F508delCFTR Protein Processing by the CFTR Corrector ABBV-2222/GLPG2222

Targeting F508del-CFTR to Develop Rational New Therapies for Cystic Fibrosis

Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination

Pharmacological Rescue of the Mutant Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Detected by Use of a Novel Fluorescence Platform